Incidence and risk factors of de novo hepatitis E virus infection after receiving liver transplantation

Abstract Organ transplant recipients with hepatitis E virus (HEV) infection bears high risk to develop chronic hepatitis, which is generally associated with immunosuppressive therapies. This study aimed to identify the incidence and predictors of de novo HEV infection in patients after receiving transplantation. We performed a large retrospective study to investigate the prevalence of anti‐HEV at baseline, incidence of de novo HEV infection after transplantation, and the risk factors of HEV infection among patients with liver transplant in China. A total of 407 liver transplant recipients were examined for the presence of anti‐HEV immunoglobulin G, IgM antibodies, and HEV RNA in serum. Basal indexes in individuals with evidence of post‐transplant HEV infection were compared with those without evidence of that, and risk factors associated with HEV infection were assessed. The prevalence of anti‐HEV at pretransplant in liver transplant recipients was 25.8% (105/407). Serum‐negative conversion occurred in 34 (32.38%) of 105 liver transplant patients. Sixty‐five out of 302 patients had de novo HEV infection after transplantation, with a cumulative incidence of 42.74% during follow‐up. After transplantation, HEV infection was associated with liver failure ( p = 0.012), hypoproteinemia ( p = 0.030) and higher level of r‐glutamyl transferase (GGT) ( p = 0.022) before transplantation. Graft rejection (OR = 0.075; p = 0.045) was negatively associated with serum‐negative conversion in patients who had positive anti‐HEV antibody before transplantation. The incidence of de novo HEV infection after transplantation were higher in China. Liver failure, hypoproteinemia, and GGT elevation may be associated with HEV infection after liver transplantation. This study suggests that prevention and control of HEV infection after liver transplantation should be paid attention in patients bearing these risk factors.